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Platinum-based treatment for small cell lung cancer (SCLC) has been established since 1995. This study investigates treatment
outcome of elderly patients (age X70 years) with SCLC over the past 20 years in a large UK cancer centre. Comparison of all-cause
survival was assessed in patients presenting between two predefined time periods: 1982–1994 and 1995–2003. All the survival
analysis were adjusted for stage and performance status and age if appropriate. Survival between different chemotherapy treatment
regimens was compared. A total of 322 elderly patients (31% of all) registered between 1982–2003 received chemotherapy for
SCLC. Patients presenting in 1995–2003 had an overall better median survival (43 vs 25 weeks) and a 1-year survival (37 vs 14%)
than patients presenting in 1982–1994 (Po0.001). This applied to patients with both limited and extensive stage disease and all age
groups. There was a trend towards the use of more platinum-based treatments in the later cohort but the use of radiotherapy
remained constant. Patients who received platinum combinations (Carboplatin or Cisplatin) had significantly improved survival over
those who received single agents or other combinations (Po0.001) and there was no significant difference between carboplatin and
cisplatin (P¼0.7). The analysis demonstrates that there has been a significant improvement in survival for elderly patients with lung
cancer treated by chemotherapy in the past 20 years despite more very elderly patients being treated with a poorer performance
status. This change is probably multifactorial and may be due to the increased use of platinum-based treatment and improved
supportive care.
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Lung cancer is the main cause of cancer deaths worldwide. The
median age at diagnosis in developed countries is approximately
68 years, and as many as 40% of patients may be older than 70
years (Bunn and Lilenbaum, 2003). In the UK, lung cancer is
primarily a disease of the elderly, with a peak incidence between
the ages of 70 and 80 years (Cancer Research Campaign, 2001). In
the treatment of small cell lung cancer (SCLC), there has been a
move to platinum-based treatment (Sundstrom et al, 2002). Local
thoracic radiotherapy and prophylactic cranial irradiation now
have a place not only in decreasing local recurrence but also in
prolonging survival (Pignon et al, 1992; Auperin et al, 1999).
Compared to the younger age group, elderly patients have
significantly more comorbidity, particularly from pulmonary and
cardiovascular disease, and may also demonstrate differences in
drug pharmacokinetics. Chemotherapy is often withheld from
elderly patients due to the fear of potential toxicities and modest
survival advantage (Earle et al, 2000; Bunn, 2002). In addition,
there are little published efficacy data for chemotherapy in this
patient group, as they have generally been under-represented in
clinical trials (Hutchins et al, 1999). This study evaluates the
survival time trends and chemotherapy outcomes in elderly
patients with SCLC, greater than or equal to 70 years of age,
treated at a single institution over a 20-year period.
PATIENTS AND METHODS
Patients
Data on all SCLC patients receiving chemotherapy at the Royal
Marsden Hospital (RMH) from 1982 to 2003 were prospectively
entered and updated on an electronic database. Recorded data
included demographic information, date of presentation to the
RMH, stage of disease, performance status (PS), treatment details,
and survival status. The diagnosis of SCLC was based on
histological or cytological features of the tumour. Tumour tissue
was reviewed by a central pathologist until 1998 when central
review was discontinued after an internal audit showed no change
in diagnosis with review. Thereafter, pathology diagnosis from the
original referring hospital was accepted unless clinical picture was
inconsistent with referring diagnosis.
Staging was based on both clinical and radiological (CXR and
CT scanning) features and was classified according to limited and
extensive stage disease defined by the Veterans Administration
Lung Study Group (Zelen, 1973). Performance status of patients
was graded according to World Health Organization criteria
(World Health Organisation, 1979).
Chemotherapy was offered to most patients with SCLC over the
20-year period. Carboplatin was used instead of cisplatin if
patients had poor renal function, deafness, could not tolerate a
fluid challenge or could not stay in hospital for the duration of
cisplatin pre- and posthydration. Patients were excluded from
analysis if they had not had adequate follow-up information or no
histological diagnosis.
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Survival was analysed by means of the proportional hazards model
(Cox, 1972) and was adjusted for the prognostic factors of stage
and PS.
Two predefined time periods, that is patients presenting
between 1982–1994 and between 1995–2003 was used for
comparison of survival. The year 1995 was chosen as a cutoff
point because platinum-based treatment was introduced around
this time to treat both limited and extensive stage SCLC patients.
Survival by time period, and also by treatment regimen, was
adjusted for stage, PS and age. In view of the changes in the local
treatment guidelines for elderly patients between the two time
periods and the three age groups, imbalances were tested for by
means of the Fisher’s exact test and the Mann–Whitney (MW)
test. Survival was analysed by means of the Cox’s proportional
hazards model and was adjusted for the prognostic factors of stage
and PS.
RESULTS
Demographics
Between 1982 and December 2003, 1163 SCLC patients were
recorded on the lung unit database. In all, 802 (69%) of these
patients were aged o70 years and 361 (31%) patients aged 70 years
or older. Of the elderly patients, 39 did not receive chemotherapy
and they have been excluded from the analysis. This report focuses
on the remaining 322 elderly patients (age X70 years), of which
157 patients presented between 1982 and 1994, and 165 patients
between 1995 and 2003.
Table 1 demonstrates patient demographic data stratified by
year of presentation. In all, 188 patients (58%) were aged 70–74
years, 108 (34%) were aged 75–79 years and 26 (8%) were aged
X80 years. The proportion of all patients over the age of 80 years
increased from 6 to 10% between the two time periods. The PS of
elderly patients treated in 1995–2003 was overall poorer than
those presenting before 1995.
Demographic and treatment data for patients with SCLC is
shown for the three age groups in Table 2. The proportion of
extensive disease patients treated with chemotherapy decreased
with the age group (P¼0.007; MW test). Patients in the 70- to
74-year-age group had a better PS than older patients (P¼0.005;
MW test). Table 3 shows the treatment modalities stratified by
time period. There was increased use of platinum compounds over
time (1982–94: 48%, 1995–2003: 75%). Similar numbers of
patients received thoracic and/or prophylactic cranial irradiation.
Survival
Overall, there has been an improvement in survival after adjusting
for stage, PS and age. Patients presenting in 1995–2003 had an
overall better median survival (43 vs 25 weeks) and a 1-year
Table 1 Demographic data stratified by year of presentation (SCLC
treated)
No. of patients (%)
1982–1994 1995–2003 Total
Patients 157 (49) 165 (51) 322
Sex
Male 95 (64) 95 (58) 190 (59)
Female 62 (39) 70 (42) 132 (41)
Age (years)
70–74 102 (65) 86 (52) 188 (58)
75–79 45 (29) 63 (38) 108 (34)
80+ 10 (6) 16 (10) 26 (8)
Stage
Limited 76 (48) 88 (53) 164 (51)
Extensive 81 (52) 77 (47) 158 (49)
Performance status
0 10 (6) 5 (3) 15 (5)
1 88 (56) 52 (32) 140 (43)
2 39 (25) 77 (47) 116 (36)
3 15 (10) 29 (18) 44 (14)
4 4 (3) 1 (1) 5 (5)
Not known 1 (1) 1 (1) 2 (1)
Table 2 Demographic data and treatment modalities in patients with
SCLC
No. of patients (%)
Age 70–
74 years
Age 75–
79 years
Age 80+
years Total
Patients 188 (58) 108 (34) 26 (8) 322
Stage
Limited 85 (45) 60 (56) 19 (73) 164 (51)
Extensive 103 (55) 48 (44) 7 (27) 158 (49)
PS
0 9 (5) 4 (4) 2 (8) 15 (5)
1 92 (49) 37 (34) 11 (42) 140 (43)
2 67 (36) 44 (41) 5 (19) 116 (36)
3 16 (9) 20 (19) 8 (31) 44 (14)
4 3 (3) 2 (2) 0 5 (2)
Not known 1 (1) 1 (1) 0 2 (1)
Treatment
Cisplatin-containing regimes 32 (17) 13 (12) 3 (12) 48 (15)
Carboplatin combinations 92 (49) 49 (45) 11 (42) 152 (47)
Nonplatinum single agents 31 (17) 40 (40) 12 (46) 83 (26)
Other nonplatinum combinations 33 (6) 6 (6) 0 39 (12)
Radiotherapy
Thoracic
(within 3 months of chemo)
17 (9) 7 (6) 4 (15) 28 (8)
PCI 13 (7) 2 (2) 0 15 (5)
Table 3 Treatment modalities stratified by year of presentation in SCLC
No. of patient (%)
Treatment 1982–1994 1995–2003 Total
Cisplatin-containing regimes 16 (10) 32 (19) 48 (15)
Carboplatin combinations 59 (38) 93 (56) 152 (47)
Nonplatinum single agents 60 (38) 23 (14) 83 (26)
Other non-platinum combinations 22 (14) 17 (10) 39 (12)
No. of cycles of chemotherapy
1 52 (33) 36 (22) 88 (27)
2 22 (14) 18 (11) 40 (12)
3 16 (10) 16 (10) 32 (10)
4 18 (11) 41 (25) 60 (19)
5 18 (11) 18 (11) 36 (11)
6+ 31 (20) 36 (22) 67 (21)
Local radiotherapy 18 (11) 10 (6) 28 (9)
prophylactic cranial irradiation 3 (2) 12 (7) 15 (5)
Treatment of elderly patients with SCLC
T Yau et al
19
British Journal of Cancer (2006) 94(1), 18–21 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
ssurvival (37 vs 14%) than patients presenting in 1982–1994
(Po0.001, Figure 1). This applied to patients with both limited and
extensive stage disease. For limited stage 1995–2003 the median
survival was 59 weeks compared to 27 in 1982–1994 (Po0.001)
and for extensive disease the same trend was seen with median
survivals of 39 vs 23 weeks (P¼0.02). Table 4 demonstrates the
improvement in survival in different elderly age groups. This
survival difference was significant in the 70- to 74-year-age group
(P¼0.001) but, possibly due to small numbers, the difference did
not reach significance in the older age groups.
Survival according to chemotherapy treatment
Patients who received platinum combinations (carboplatin or
cisplatin) had significantly improved survival over those who
received single agents or other combinations (Po0.001) (Figure 2).
There was no significant difference between carboplatin and
cisplatin (P¼0.7).
DISCUSSION
This study suggests that there has been a significant improvement
in survival for SCLC elderly patients (age X70 years) receiving
treatment over the past 20 years despite the trend to treat more of
the very elderly and patients with a worse PS. This improvement is
still present when patients are controlled for sex, stage and PS,
suggesting that this is due to advances in patient management
adjunctive therapies and in particular the use of platinum (and
carboplatin)-based therapy rather than earlier presentation of the
disease.
In SCLC, combination chemotherapy has been an established
treatment for decades. In contrast to elderly patients with NSCLC,
the majority of elderly patients with SCLC will receive active
treatment (chemotherapy and radiotherapy) – only 39/361 of our
patients did not receive treatment (Brown et al, 1996). Pooled data
of the Southwest Oncology Group (Albain et al, 1990) and CALGB
(Spiegelman et al, 1989) showed that age was a significant
predictor favouring the younger patient for both limited and
extensive disease SCLC although a large French retrospective
review of SCLC patients using numerous regimens found no such
correlation (Lebitasy et al, 2001). Our median survivals for all
these elderly patients are still in the range of reported studies.
Single-agent chemotherapy, namely oral etoposide, was initially
thought to be a reasonable treatment for elderly patients with
SCLC (Smit et al, 1989). However, two large randomised trials
demonstrated inferior survival when this regime was compared to
combination chemotherapy (Girling, 1996; Souhami et al, 1997)
and our data would support this in an nontrial setting. In limited
stage SCLC, Siu et al (1996) demonstrated that combination
chemotherapy has similar efficacy in both young and elderly
patients and Murray et al (1998) showed that treatment toxicities
may be minimised while maintaining similar outcomes by giving
Table 4 Survival differences among elderly SCLC patients between
1982–1994 and 1995–2003
Year 1982–1994 1995–2003 P values
Age 70–74 years Weeks Weeks
MS overall
a 31 47 0.001
LD 33 60 0.03
ED 24 36 0.004
1-year survival 21% 44%
Age 75–80 years
MS overall
a 25 weeks 28 weeks 0.06
LD 28 49 0.001
ED 27 27 0.7
1 year survival 6% 25%
Age 480 years
MS overall
a 9 weeks 34 weeks 0.2
LD n¼19 5 62 0.02
ED n¼7 4 34 1.0
1-year survival 0% 30%
MS¼median survival.
aResults are adjusted for stage and PS.
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Figure 1 Survival by year of presentation graph.
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Figure 2 Survival by treatment.
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a longer course of chemotherapy. However, subset analysis of
an Intergroup trial found that elderly patients (age 4 70 years)
obtained similar responses and survival figures to younger patients
and that the elderly subgroup did significantly worse when treated
by only two cycles of chemotherapy (Yuen et al, 2000). There was
no major change in the number of cycles given in our populations
over time. In extensive stage SCLC, Pujol et al (2001) found that
elderly patients (age 4 70 years) had similar response rates and
survival to young patients when they were treated by cisplatin
combinations and there was no statistically significant impact of
age on these outcomes.
Platinum-based treatment with etoposide has been our treat-
ment of choice for all SCLC patients since around 1995. Outcome
improvements in SCLC patients are not restricted to any particular
stage or age group. Given that carboplatin was generally used
when patients were not considered fit enough for cisplatin the
results with carboplatin are very reassuring and the carboplatin
etoposide is now the standard in the elderly in our unit. While
the benefits of radiotherapy on local disease control have been
known for 20 years, the survival benefits of radiotherapy are a
more recent addition to the general consensus. (Auperin et al,
1999). In our study, the impact of radiotherapy on the differences
in survival between the two cohorts in SCLC patients is negligible
as there were a similar proportion of patients who received
thoracic and/or prophylactic cranial irradiation between the
two cohorts. There are few data in the literature reporting the
outcomes of chemotherapy treatment in elderly patients with
SCLC. Most studies available include elderly patients with SCLC
up to 75 years old. In our study, we have analysed the outcome of
322 elderly patients older than 70 years, and 134 patients older
than 75 years with SCLC. This is the largest series in the literature
so far.
This improvement in treatment outcomes overall might also be
attributed to other factors. Changes in guidelines and different
working procedures have resulted in a very large percentage of
patients with lung cancer being referred for oncological assess-
ment. Better assessment of comorbidity and PS of patients has
resulted in better selection of patients for chemotherapy. There is
now better supportive care, such as antiemetics, laxatives,
antibiotics, etc. available for these patients, so that courses of
treatment of appropriate intensity and duration can be safely
administered. The contribution of nutritional status, social and
family support are of course not easily quantifiable and difficult to
evaluate over a long time period but may also be relevant. Last but
not least, advances in the medical oncology treatment of lung
cancer, including the use of second-line therapies may also have
played a role in the improvement in survival over the recent years
in this elderly population (age X70 years).
In conclusion, the outcome for elderly patients with SCLC in our
sector has globally improved. In our experience, carboplatin
combinations have as good an outcome and better toxicity profile
than other combinations or nonplatinum single agents chemo-
therapy in the elderly with SCLC.
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